vs
Loews Corporation（L）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Loews Corporation的季度营收约是Revvity的1.1倍（$827.0M vs $772.1M），Loews Corporation净利率更高（48.6% vs 12.7%，领先35.9%），Revvity同比增速更快（5.9% vs 4.8%），Loews Corporation自由现金流更多（$426.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 7.9%）
Loews Corporation是一家总部位于美国的多元化综合企业集团，旗下子公司业务覆盖财产保险、天然气管道运输、酒店运营、油气勘探生产等核心领域，主要服务北美市场的商业、消费者及工业客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
L vs RVTY — 直观对比
营收规模更大
L
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出1.0%
4.8%
净利率更高
L
高出35.9%
12.7%
自由现金流更多
L
多$264.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $827.0M | $772.1M |
| 净利润 | $402.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 65.4% | 14.5% |
| 净利率 | 48.6% | 12.7% |
| 营收同比 | 4.8% | 5.9% |
| 净利润同比 | 115.0% | 3.9% |
| 每股收益（稀释后） | $1.93 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LRVTY
| Q4 25 | $827.0M | $772.1M | ||
| Q3 25 | $732.0M | $698.9M | ||
| Q2 25 | $769.0M | $720.3M | ||
| Q1 25 | $846.0M | $664.8M | ||
| Q4 24 | $789.0M | $729.4M | ||
| Q3 24 | $683.0M | $684.0M | ||
| Q2 24 | $711.0M | $691.7M | ||
| Q1 24 | $710.0M | $649.9M |
净利润LRVTY
| Q4 25 | $402.0M | $98.4M | ||
| Q3 25 | $504.0M | $46.7M | ||
| Q2 25 | $391.0M | $53.9M | ||
| Q1 25 | $370.0M | $42.2M | ||
| Q4 24 | $187.0M | $94.6M | ||
| Q3 24 | $401.0M | $94.4M | ||
| Q2 24 | $369.0M | $55.4M | ||
| Q1 24 | $457.0M | $26.0M |
毛利率LRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率LRVTY
| Q4 25 | 65.4% | 14.5% | ||
| Q3 25 | 94.1% | 11.7% | ||
| Q2 25 | 70.1% | 12.6% | ||
| Q1 25 | 60.8% | 10.9% | ||
| Q4 24 | 23.8% | 16.3% | ||
| Q3 24 | 80.5% | 14.3% | ||
| Q2 24 | 71.3% | 12.4% | ||
| Q1 24 | 88.6% | 6.8% |
净利率LRVTY
| Q4 25 | 48.6% | 12.7% | ||
| Q3 25 | 68.9% | 6.7% | ||
| Q2 25 | 50.8% | 7.5% | ||
| Q1 25 | 43.7% | 6.4% | ||
| Q4 24 | 23.7% | 13.0% | ||
| Q3 24 | 58.7% | 13.8% | ||
| Q2 24 | 51.9% | 8.0% | ||
| Q1 24 | 64.4% | 4.0% |
每股收益（稀释后）LRVTY
| Q4 25 | $1.93 | $0.86 | ||
| Q3 25 | $2.43 | $0.40 | ||
| Q2 25 | $1.87 | $0.46 | ||
| Q1 25 | $1.74 | $0.35 | ||
| Q4 24 | $0.87 | $0.77 | ||
| Q3 24 | $1.82 | $0.77 | ||
| Q2 24 | $1.67 | $0.45 | ||
| Q1 24 | $2.05 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.0B | $919.9M |
| 总债务越低越好 | $8.4B | — |
| 股东权益账面价值 | $18.7B | $7.3B |
| 总资产 | $86.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.45× | — |
8季度趋势，按日历期对齐
现金及短期投资LRVTY
| Q4 25 | $6.0B | $919.9M | ||
| Q3 25 | $5.4B | $931.4M | ||
| Q2 25 | $4.5B | $991.8M | ||
| Q1 25 | $4.4B | $1.1B | ||
| Q4 24 | $4.6B | $1.2B | ||
| Q3 24 | $5.2B | $1.2B | ||
| Q2 24 | $4.9B | $2.0B | ||
| Q1 24 | $5.4B | $1.7B |
总债务LRVTY
| Q4 25 | $8.4B | — | ||
| Q3 25 | $8.4B | — | ||
| Q2 25 | $7.9B | — | ||
| Q1 25 | $8.4B | — | ||
| Q4 24 | $8.9B | — | ||
| Q3 24 | $8.8B | — | ||
| Q2 24 | $8.6B | — | ||
| Q1 24 | $8.4B | — |
股东权益LRVTY
| Q4 25 | $18.7B | $7.3B | ||
| Q3 25 | $18.3B | $7.4B | ||
| Q2 25 | $17.5B | $7.6B | ||
| Q1 25 | $17.2B | $7.6B | ||
| Q4 24 | $17.1B | $7.7B | ||
| Q3 24 | $17.4B | $7.9B | ||
| Q2 24 | $16.4B | $7.9B | ||
| Q1 24 | $16.2B | $7.8B |
总资产LRVTY
| Q4 25 | $86.3B | $12.2B | ||
| Q3 25 | $85.9B | $12.1B | ||
| Q2 25 | $84.7B | $12.4B | ||
| Q1 25 | $83.1B | $12.4B | ||
| Q4 24 | $81.9B | $12.4B | ||
| Q3 24 | $83.6B | $12.8B | ||
| Q2 24 | $81.1B | $13.4B | ||
| Q1 24 | $80.9B | $13.4B |
负债/权益比LRVTY
| Q4 25 | 0.45× | — | ||
| Q3 25 | 0.46× | — | ||
| Q2 25 | 0.45× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.52× | — | ||
| Q3 24 | 0.51× | — | ||
| Q2 24 | 0.52× | — | ||
| Q1 24 | 0.52× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $617.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $426.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 51.5% | 21.0% |
| 资本支出强度资本支出/营收 | 23.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.53× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.7B | $509.4M |
8季度趋势，按日历期对齐
经营现金流LRVTY
| Q4 25 | $617.0M | $182.0M | ||
| Q3 25 | $920.0M | $138.5M | ||
| Q2 25 | $1.0B | $134.3M | ||
| Q1 25 | $736.0M | $128.2M | ||
| Q4 24 | $941.0M | $174.2M | ||
| Q3 24 | $934.0M | $147.9M | ||
| Q2 24 | $952.0M | $158.6M | ||
| Q1 24 | $198.0M | $147.6M |
自由现金流LRVTY
| Q4 25 | $426.0M | $161.8M | ||
| Q3 25 | $764.0M | $120.0M | ||
| Q2 25 | $872.0M | $115.5M | ||
| Q1 25 | $638.0M | $112.2M | ||
| Q4 24 | $767.0M | $149.8M | ||
| Q3 24 | $794.0M | $125.6M | ||
| Q2 24 | $793.0M | $136.6M | ||
| Q1 24 | $39.0M | $129.7M |
自由现金流率LRVTY
| Q4 25 | 51.5% | 21.0% | ||
| Q3 25 | 104.4% | 17.2% | ||
| Q2 25 | 113.4% | 16.0% | ||
| Q1 25 | 75.4% | 16.9% | ||
| Q4 24 | 97.2% | 20.5% | ||
| Q3 24 | 116.3% | 18.4% | ||
| Q2 24 | 111.5% | 19.7% | ||
| Q1 24 | 5.5% | 20.0% |
资本支出强度LRVTY
| Q4 25 | 23.1% | 2.6% | ||
| Q3 25 | 21.3% | 2.6% | ||
| Q2 25 | 17.4% | 2.6% | ||
| Q1 25 | 11.6% | 2.4% | ||
| Q4 24 | 22.1% | 3.4% | ||
| Q3 24 | 20.5% | 3.3% | ||
| Q2 24 | 22.4% | 3.2% | ||
| Q1 24 | 22.4% | 2.7% |
现金转化率LRVTY
| Q4 25 | 1.53× | 1.85× | ||
| Q3 25 | 1.83× | 2.97× | ||
| Q2 25 | 2.57× | 2.49× | ||
| Q1 25 | 1.99× | 3.03× | ||
| Q4 24 | 5.03× | 1.84× | ||
| Q3 24 | 2.33× | 1.57× | ||
| Q2 24 | 2.58× | 2.87× | ||
| Q1 24 | 0.43× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
L
| Transportation And Storage Of Natural Gas And NG Ls And Ethane Supply And Transportation Services | $601.0M | 73% |
| Lodging And Related Services | $226.0M | 27% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
